Robot suit helps MS patients walk better?
NCT ID NCT06615947
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether a robotic walking system called Atalante could help people with multiple sclerosis walk better. Sixty participants were randomly assigned to either use the robot or receive standard physical therapy for 8 weeks. The main goal was to see if the robot improved walking speed more than conventional rehab.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Atalante self-balancing walking system (robotic exoskeleton)
- What this could lead to
- If successful, this could offer a new, more effective way to improve walking speed and mobility for people with multiple sclerosis.
- What could go wrong
- This is a small, completed trial with 60 participants. The results may not apply to all MS patients, and the exoskeleton may not be widely available or affordable.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
60 people
The number who actually took part.
- Started
-
Feb 2023
- Finished
-
Mar 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * • Male or female, between 18 and 75 years of age. * Confirmed diagnosis of MS. * EDSS from 6.0 to 7.0. * Able to maintain the upright position on a daily basis. * Stable course of disease-modifying therapy over the past 6 months. * Clinical comorbidity asymptomatic (i.e., no underlying cardiovascular disease) * Height: between approximately 1.50 m. and 1.90 m. * Willingness to visit the Multiple Sclerosis Center of Catalonia (Cemcat) for testing and training. * Gait disorder conditioned by paresis or hemiparesis associated with ataxia or sensory problems. * Patient having given written consent. Atalante is able to accommodate the following limb lengths: * Thigh: 380-460mm. * Distance between the ground and the joint space of the knee (to be measured while wearing the shoes they intend to wear with Atalante): * 457-607mm for patient with an ankle dorsiflexion ≥ 16° * 457-577mm for patient with an ankle dorsiflexion between 13° et 16° * 457-567mm for patient with an ankle dorsiflexion between 10° et 13° * 457-557mm for patient with an ankle dorsiflexion between 0° and 10° * Hip with less or equal to 460mm when seated. * Maximum weight: 90 kg. Exclusion Criteria: * • Pregnancy. * Starting or switching from fampridine (Fampyra®) in the last 4 weeks. * Height and weight outside the secure standard of safe use, described in the safety guides. * Contraindications for Atalante training (eg, bone instability, history of osteoporosis or osteoporotic fractures). * Subjects under Corticosteroids treatment or relapse. * Changes in disease-modifying and symptomatic therapy for MS during the study period. * Subjects with psychiatric or cognitive comorbidities that may interfere with the trial. * Whose joint centers cannot be aligned Atalante's. * Ranges of motion below: * Knee: 5° extension, 110° flexion * Ankle: 0° dorsiflexion, 9° plantar flexion, 18° inversion and eversion * Hip: 115° flexion, 15° extension, 17° abduction, 10° adduction, 10° * medial rotation, 20° lateral rotation * Severe spasticity (greater than Ashworth 3) or uncontrolled clonus. * Severe concurrent medical diseases: infections, circulatory, heart or lung, pressure sores. * Active implantable medical device.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Gait disorders, neurologic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre d'Esclerosi Mútiple de Catalunya (Cemcat) - Barcelona, Hospital Universitari Vall d'Hebron
Barcelona, Barcelona, 08035, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can exercise rebuild muscle and balance in MS?
- Can diet ease the crushing fatigue of multiple sclerosis?
- One-Time CAR-T infusion tested against progressive MS
- Can PET scans reveal hidden brain inflammation in MS?
- Can a pill rebuild the Brain's insulation? MS trial puts remyelination to the test
- Migraines and tension headaches may be hidden companions to multiple sclerosis